[go: up one dir, main page]

CN111372936A - Mcl-1选择性抑制剂及其制备和用途 - Google Patents

Mcl-1选择性抑制剂及其制备和用途 Download PDF

Info

Publication number
CN111372936A
CN111372936A CN201880075917.4A CN201880075917A CN111372936A CN 111372936 A CN111372936 A CN 111372936A CN 201880075917 A CN201880075917 A CN 201880075917A CN 111372936 A CN111372936 A CN 111372936A
Authority
CN
China
Prior art keywords
alkyl
radical
optionally substituted
substituted
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880075917.4A
Other languages
English (en)
Other versions
CN111372936B (zh
Inventor
刘志华
陈坤成
袁保昆
焦楠
解博闻
闵汪洋
许新合
刘希杰
孙莹
徐枫
孙颖慧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centaurus Biopharma Co Ltd
Original Assignee
Centaurus Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201711189194.4A external-priority patent/CN109824690A/zh
Priority claimed from CN201810425784.0A external-priority patent/CN110452253A/zh
Application filed by Centaurus Biopharma Co Ltd filed Critical Centaurus Biopharma Co Ltd
Publication of CN111372936A publication Critical patent/CN111372936A/zh
Application granted granted Critical
Publication of CN111372936B publication Critical patent/CN111372936B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供了Mcl‑1选择性抑制剂及其制备和用途；本发明同时提供了一系列由通式(I)所表示的化合物及其药学上可接受的盐、溶剂化物、多晶型物或前药、包含这些化合物的药物组合物，以及用此类化合物治疗由过度表达或失调的MCL‑1蛋白引起的或加重的疾病的方法。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201880075917.4A 2017-11-23 2018-11-22 Mcl-1选择性抑制剂及其制备和用途 Active CN111372936B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2017111891944 2017-11-23
CN201711189194.4A CN109824690A (zh) 2017-11-23 2017-11-23 Mcl-1选择性抑制剂及其制备和用途
CN2018104257840 2018-05-08
CN201810425784.0A CN110452253A (zh) 2018-05-08 2018-05-08 Mcl-1选择性抑制剂及其制备和用途
PCT/CN2018/117014 WO2019101144A1 (zh) 2017-11-23 2018-11-22 Mcl-1选择性抑制剂及其制备和用途

Publications (2)

Publication Number Publication Date
CN111372936A true CN111372936A (zh) 2020-07-03
CN111372936B CN111372936B (zh) 2022-12-02

Family

ID=66631350

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880075917.4A Active CN111372936B (zh) 2017-11-23 2018-11-22 Mcl-1选择性抑制剂及其制备和用途

Country Status (2)

Country Link
CN (1) CN111372936B (zh)
WO (1) WO2019101144A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113024577B (zh) * 2019-12-09 2023-06-30 首药控股(北京)股份有限公司 一种抗凋亡蛋白选择性抑制剂的制备方法
CN113024578A (zh) * 2019-12-09 2021-06-25 首药控股(北京)有限公司 一种mcl1选择性抑制剂的多晶型物及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015097123A1 (en) * 2013-12-23 2015-07-02 Les Laboratoires Servier New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
WO2016207217A1 (en) * 2015-06-23 2016-12-29 Les Laboratoires Servier New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
WO2016207216A1 (en) * 2015-06-23 2016-12-29 Les Laboratoires Servier New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
WO2016207225A1 (en) * 2015-06-23 2016-12-29 Les Laboratoires Servier New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
CN108424417A (zh) * 2017-12-21 2018-08-21 河南美泰宝生物制药有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
CN109824690A (zh) * 2017-11-23 2019-05-31 北京赛林泰医药技术有限公司 Mcl-1选择性抑制剂及其制备和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3567043B1 (en) * 2017-01-05 2023-12-06 Henan Genuine Biotech Co., Ltd. 2-[[5-[(4-hydroxy-3-chloro-2-methyl)-phenyl]-thieno[2,3-d]pyrimidin-4-yl]oxy]-3-(2-methoxybenzene)propanoic acid derivatives as mcl-1 and bcl-2 inhibitors for treating cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015097123A1 (en) * 2013-12-23 2015-07-02 Les Laboratoires Servier New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
WO2016207217A1 (en) * 2015-06-23 2016-12-29 Les Laboratoires Servier New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
WO2016207216A1 (en) * 2015-06-23 2016-12-29 Les Laboratoires Servier New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
WO2016207225A1 (en) * 2015-06-23 2016-12-29 Les Laboratoires Servier New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
CN109824690A (zh) * 2017-11-23 2019-05-31 北京赛林泰医药技术有限公司 Mcl-1选择性抑制剂及其制备和用途
CN108424417A (zh) * 2017-12-21 2018-08-21 河南美泰宝生物制药有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用

Also Published As

Publication number Publication date
CN111372936B (zh) 2022-12-02
WO2019101144A1 (zh) 2019-05-31

Similar Documents

Publication Publication Date Title
CN109715626A (zh) 作为fgfr抑制剂的杂环化合物
CN113784970A (zh) Erk抑制剂及其应用
JOP20210001A1 (ar) مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2
JP2008510770A5 (zh)
JP2019522055A5 (zh)
JP2014500870A5 (zh)
JP2016515561A5 (zh)
JP2017509586A5 (zh)
JP2014503574A5 (zh)
EA201990902A1 (ru) Ингибиторы тирозинкиназы брутона
JP2019524883A5 (zh)
JP2015537020A5 (zh)
JP2016503799A5 (zh)
JP2016522266A5 (zh)
JP2015522650A5 (zh)
JP2017523169A5 (zh)
CN114761411A (zh) 作为erk抑制剂的螺环类化合物及其应用
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
JP2019505529A5 (zh)
JP2017524013A5 (zh)
JP2016531868A5 (zh)
JP2017517565A5 (zh)
CN114072396A (zh) 作为dna-pk抑制剂的喹啉和噌啉衍生物
JP2016531126A5 (zh)
JP2017531677A5 (zh)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant